nach oben

Erschienen in:

09.01.2023 | Original Article

Glomerular expression and urinary excretion of fatty acid-binding protein 4 in IgA nephropathy

verfasst von: Marenao Tanaka, Norihito Moniwa, Chieko Nogi, Toshiki Kano, Megumi Matsumoto, Akiko Sakai, Takuto Maeda, Hideki Takizawa, Yayoi Ogawa, Katsuhiko Asanuma, Yusuke Suzuki, Masato Furuhashi

Erschienen in: Journal of Nephrology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Fatty acid-binding protein 4 (FABP4) is secreted from adipocytes and macrophages in adipose tissue and acts as an adipokine. It has recently been reported that FABP4, but not liver-type FABP (L-FABP/FABP1), is also expressed in injured glomerular endothelial cells and infiltrating macrophages in the glomerulus and that urinary FABP4 (U-FABP4) is associated with proteinuria and kidney function impairment in nephrotic patients. However, the link between glomerular FABP4 and U-FABP4 has not been fully addressed in IgA nephropathy (IgAN).

Methods

We investigated the involvement of FABP4 in human and mouse IgAN.

Results

In patients with IgAN (n = 23), the ratio of FABP4-positive area to total area within glomeruli (G-FABP4-Area) and U-FABP4 were positively correlated with proteinuria and were negatively correlated with eGFR. In 4–28-week-old male grouped ddY mice, a spontaneous IgAN-prone mouse model, FABP4 was detected in glomerular endothelial cells and macrophages, and G-FABP4-Area was positively correlated with urinary albumin-to-creatinine ratio (r = 0.957, P < 0.001). Endoplasmic reticulum stress markers were detected in glomeruli of human and mouse IgAN. In human renal glomerular endothelial cells, FABP4 was induced by treatment with vascular endothelial growth factor and was secreted from the cells. Treatment of human renal glomerular endothelial cells or mouse podocytes with palmitate-bound recombinant FABP4 significantly increased gene expression of inflammatory cytokines and endoplasmic reticulum stress markers, and the effects of FABP4 in podocytes were attenuated in the presence of an anti-FABP4 antibody.

Conclusion

FABP4 in the glomerulus contributes to proteinuria in IgAN, and U-FABP4 level is a useful surrogate biomarker for glomerular damage in IgAN.

Nur mit Berechtigung zugänglich

Rodrigues JC, Haas M, Reich HN (2017) IgA nephropathy. Clin J Am Soc Nephrol 12:677–686PubMedCentralPubMed

Pattrapornpisut P, Avila-Casado C, Reich HN (2021) IgA nephropathy: core curriculum 2021. Am J Kidney Dis 78:429–441PubMed

Koyama A, Igarashi M, Kobayashi M (1997) Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 29:526–532PubMed

Ruan XZ, Varghese Z, Moorhead JF (2009) An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 5:713–721PubMed

Izquierdo-Lahuerta A, Martinez-Garcia C, Medina-Gomez G (2016) Lipotoxicity as a trigger factor of renal disease. J Nephrol 29:603–610PubMed

Osanami A, Tanaka M, Furuhashi M et al (2022) Increased LDL cholesterol level is associated with deterioration of renal function in males. Clin Kidney J 15:1888–1895PubMedCentralPubMed

Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415–445PubMed

Hotamisligil GS (2017) Inflammation, metaflammation and immunometabolic disorders. Nature 542:177–185PubMed

Urano F, Wang X, Bertolotti A et al (2000) Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287:664–666PubMed

10.

Deng J, Lu PD, Zhang Y et al (2004) Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol 24:10161–10168PubMedCentralPubMed

11.

Hu P, Han Z, Couvillon AD et al (2006) Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol Cell Biol 26:3071–3084PubMedCentralPubMed

12.

Ozcan U, Yilmaz E, Ozcan L et al (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313:1137–1140PubMedCentralPubMed

13.

Ishimura S, Furuhashi M, Mita T et al (2014) Reduction of endoplasmic reticulum stress inhibits neointima formation after vascular injury. Sci Rep 4:6943PubMedCentralPubMed

14.

Koyama M, Furuhashi M, Ishimura S et al (2014) Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 306:H1314-1323PubMed

15.

Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7:489–503PubMedCentralPubMed

16.

Furuhashi M (2019) Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. J Atheroscler Thromb 26:216–232PubMedCentralPubMed

17.

Kamijo A, Kimura K, Sugaya T et al (2002) Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 62:1628–1637PubMed

18.

Kamijo A, Kimura K, Sugaya T et al (2004) Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 143:23–30PubMed

19.

Kamijo-Ikemori A, Sugaya T, Kimura K (2014) Novel urinary biomarkers in early diabetic kidney disease. Curr Diab Rep 14:513PubMed

20.

Furuhashi M, Tuncman G, Gorgun CZ et al (2007) Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447:959–965PubMedCentralPubMed

21.

Ishimura S, Furuhashi M, Watanabe Y et al (2013) Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS ONE 8:e81318PubMedCentralPubMed

22.

Fuseya T, Furuhashi M, Matsumoto M et al (2017) Ectopic fatty acid-binding protein 4 expression in the vascular endothelium is involved in neointima formation after vascular injury. J Am Heart Assoc 6:e006377PubMedCentralPubMed

23.

Tanaka M, Furuhashi M, Okazaki Y et al (2014) Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction. Nephron Clin Pract 128:345–351PubMed

24.

Okazaki Y, Furuhashi M, Tanaka M et al (2014) Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction. PLoS ONE 9:e115429PubMedCentralPubMed

25.

Tanaka M, Furuhashi M, Moniwa N et al (2020) Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria. BMC Nephrol 21:459PubMedCentralPubMed

26.

KDIGO (2012) Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl 2:209–217

27.

Yuzawa Y, Yamamoto R, Takahashi K et al (2016) Evidence-based clinical practice guidelines for IgA nephropathy 2014. Clin Exp Nephrol 20:511–535PubMedCentralPubMed

28.

Matsuo S, Imai E, Horio M et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMed

29.

Xu A, Wang Y, Xu JY et al (2006) Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52:405–413PubMed

30.

Suzuki H, Suzuki Y (2018) Murine models of human IgA nephropathy. Semin Nephrol 38:513–520PubMed

31.

Okazaki K, Suzuki Y, Otsuji M et al (2012) Development of a model of early-onset IgA nephropathy. J Am Soc Nephrol 23:1364–1374PubMedCentralPubMed

32.

Mundel P, Reiser J, Zuniga Mejia Borja A et al (1997) Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236:248–258PubMed

33.

Asanuma K, Shirato I, Ishidoh K et al (2002) Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int 62:822–831PubMed

34.

Furuhashi M, Mita T, Moniwa N et al (2015) Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. Hypertens Res 38:252–259PubMed

35.

Mita T, Furuhashi M, Hiramitsu S et al (2015) FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Silver Spring) 23:359–367PubMed

36.

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458PubMed

37.

Elmasri H, Karaaslan C, Teper Y et al (2009) Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 23:3865–3873PubMedCentralPubMed

38.

Elmasri H, Ghelfi E, Yu CW et al (2012) Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis 15:457–468PubMedCentralPubMed

39.

Furuhashi M, Fuseya T, Murata M et al (2016) Local production of fatty acid-binding protein 4 in epicardial/perivascular fat and macrophages is linked to coronary atherosclerosis. Arterioscler Thromb Vasc Biol 36:825–834PubMed

40.

Yao F, Li Z, Ehara T et al (2015) Fatty Acid-Binding Protein 4 mediates apoptosis via endoplasmic reticulum stress in mesangial cells of diabetic nephropathy. Mol Cell Endocrinol 411:232–242PubMed

41.

Prentice KJ, Saksi J, Robertson LT et al (2021) A hormone complex of FABP4 and nucleoside kinases regulates islet function. Nature 600:720–726PubMedCentralPubMed

42.

D’Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179–196PubMed

43.

Hotta O, Miyazaki M, Furuta T et al (2001) Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 38:736–743PubMed

44.

Pozzi C, Andrulli S, Del Vecchio L et al (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157–163PubMed

45.

Kawamura T, Yoshimura M, Miyazaki Y et al (2014) A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 29:1546–1553PubMedCentralPubMed

46.

Hirano K, Matsuzaki K, Yasuda T et al (2019) Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy. JAMA Netw Open 2:e194772PubMedCentralPubMed

47.

Medjeral-Thomas NR, O’Shaughnessy MM (2020) Complement in IgA nephropathy: the role of complement in the pathogenesis, diagnosis, and future management of IgA nephropathy. Adv Chronic Kidney Dis 27:111–119PubMed

48.

Zhao N, Hou P, Lv J et al (2012) The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82:790–796PubMedCentralPubMed

49.

Suzuki H, Allegri L, Suzuki Y et al (2016) Galactose-deficient IgA1 as a candidate urinary polypeptide marker of IgA nephropathy? Dis Markers 2016:7806438PubMedCentralPubMed

50.

Irabu H, Shimizu M, Kaneko S et al (2021) Apoptosis inhibitor of macrophage as a biomarker for disease activity in Japanese children with IgA nephropathy and Henoch-Schonlein purpura nephritis. Pediatr Res 89:667–672PubMed

51.

Takahata A, Arai S, Hiramoto E et al (2020) Crucial role of AIM/CD5L in the development of glomerular inflammation in IgA nephropathy. J Am Soc Nephrol 31:2013–2024PubMedCentralPubMed

52.

Tomino Y (2016) Diagnosis and treatment of patients with IgA nephropathy in Japan. Kidney Res Clin Pract 35:197–203PubMedCentralPubMed

53.

Obajdin J, Cotter M, Snelling S et al (2018) Fatty-acid binding protein 4 (FABP4) as a potential preclinical biomarker of drug-induced kidney injury. Toxicol Sci 166:441–450PubMed

54.

Shrestha S, Sunaga H, Hanaoka H et al (2018) Circulating FABP4 is eliminated by the kidney via glomerular filtration followed by megalin-mediated reabsorption. Sci Rep 8:16451PubMedCentralPubMed

Titel: Glomerular expression and urinary excretion of fatty acid-binding protein 4 in IgA nephropathy
verfasst von: Marenao Tanaka
Norihito Moniwa
Chieko Nogi
Toshiki Kano
Megumi Matsumoto
Akiko Sakai
Takuto Maeda
Hideki Takizawa
Yayoi Ogawa
Katsuhiko Asanuma
Yusuke Suzuki
Masato Furuhashi
Publikationsdatum: 09.01.2023
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 2/2023
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-022-01551-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Lessons for the clinical nephrologist: lumasiran as the future cornerstone treatment for patients with primary hyperoxaluria type 1?

Giant dilation of the urinary tract mimicking an abdominal mass

Long-term outcomes of add-on direct renin inhibition in igA nephropathy: a propensity score-matched cohort study

Predictive prognostic value of glomerular C3 deposition in IgA nephropathy

Citric acid-based bicarbonate dialysate attenuates aortic arch calcification in maintenance hemodialysis patients: a retrospective observational study